Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (10348)	6/4/1999 11:50:00 AM
From: aknahow	Respond to of 17367

Yes, but I was including the fact that there have been buy interest messages far in excess of daily trades. There has also been daily reporting of institution purchases. so this is not a case, IMO, of we have low volume and we can move either way big time. My whole point was, clear evidence of institutional interest, but low volume indicates no hurry to buy at any price, as of this moment. Lots of potential supply buy retail holders that don't really know much about XOMA other than they have a loss. News can of course change the whole picture, making institutions more willing to buy and present holders less willing to sell.

To: Robert K. who wrote (10348)	6/9/1999 1:52:00 AM
From: aknahow	Read Replies (3) \| Respond to of 17367

Your failure to find this may cause you to eat your heart out. This article goes straight to the heart of the matter. Available free with registration. Current May 29 issue. thelancet.com Endotoxin and immune activation in chronic heart failure: a prospective cohort study <<<<<<< These results lend credance to the hypothesis that bacterial endotoxin may be an important stimulus of immune activation in patients with chronic heart failure. This finding may open various options for treatment of patients with chronic heart failure that could be directed against bacteria in the bowel, the translocation process, and endotoxin itself, the binding sites of bacterial endotoxin on immune competent cells, or both.>>>>>>>>>>> Above is very minimal quote from entire article.